Neurocrine Biosciences (NBIX) fits the profile of a company that could appeal to investors seeking a blend of growth and value—often referred to as GARP (Growth at a Reasonable Price). This strategy, famously championed by legendary fund manager Peter Lynch, focuses on identifying companies that are expanding their earnings at a sustainable pace while trading at valuations that don’t fully reflect that potential. Lynch’s approach, detailed in his book One Up on Wall Street, emphasizes buying growing businesses with solid fundamentals and reasonable price tags, steering clear of overhyped stocks. He also advocates for patience and long-term holding, letting compounding work its magic over years rather than months.
Neurocrine Biosciences (NASDAQ:NBIX) is a neuroscience-focused biopharmaceutical company with approved treatments for conditions like tardive dyskinesia and Huntington’s disease-related chorea, as well as a pipeline targeting neurological, neuroendocrine, and neuropsychiatric disorders. Below, we break down why NBIX earns strong marks under the Peter Lynch framework and what this means for GARP-oriented investors.
Why Neurocrine Biosciences Fits the Peter Lynch Screen
The Peter Lynch screen is built around a core set of criteria designed to weed out both stagnant and dangerously fast-growing companies while highlighting those with healthy financials and attractive valuations. NBIX passes every major test, often by a wide margin.
Sustainable Earnings Growth
Lynch insisted that earnings per share (EPS) grow between 15% and 30% annually over five years—fast enough to drive returns but not so fast that growth becomes unsustainable. NBIX delivers a 5-year EPS growth rate of 29.09%, right at the upper end of his ideal range. This growth is backed by a strong revenue trajectory of 22.29% annually over the same period, and recent revenue growth accelerated to 28.59% in the past year. The company’s expansion is grounded in real commercial success, particularly with its lead drug INGREZZA.
Valuation That Compensates for Growth
The PEG ratio (price/earnings divided by earnings growth) is a cornerstone of Lynch’s method. He looked for a PEG below 1.0, signaling that the stock isn’t overpriced relative to its growth rate. NBIX’s PEG (based on past 5-year growth) stands at 0.86, well within that threshold. Its trailing P/E of 24.88 is actually cheaper than 93.57% of peers in the biotechnology industry, while its forward P/E of 16.74 undercuts the S&P 500’s forward multiple of 21.01. In short, you’re paying a reasonable price for above-average growth.
Financial Health and Profitability
Lynch favored companies with strong balance sheets and high returns on equity, viewing them as safer long-term bets. NBIX has zero debt—its Debt/Equity ratio is exactly 0.0—and a current ratio of 2.93, meaning it has nearly three times the current assets needed to cover short-term liabilities. Return on Equity (ROE) is 19.62%, comfortably above the 15% minimum in the screen. These metrics confirm a business that is profitable, well-capitalized, and not reliant on borrowing to fund growth.
Additional Lynch-Friendly Traits
Beyond the headline filters, Lynch liked companies that buy back shares, have manageable institutional ownership, and generate ample cash. NBIX’s return on invested capital (ROIC) of 13.53% outperforms 95% of its industry peers, and its free cash flow is strong. While the company does not pay dividends (common for growth-stage biotechs), its capital allocation focuses on reinvesting in its pipeline, which aligns with long-term value creation.
High-Level Fundamental Report Summary
Our fundamental analysis of NBIX awards it a strong overall rating of 7 out of 10, which reflects a company with solid profitability, excellent health, and attractive growth at a fair valuation.
-
Profitability (8/10): NBIX’s profit margin of 21.55% and operating margin of 25.75% are among the best in the biotechnology industry. Return on assets and return on invested capital both rank in the top 5% of peers.
-
Health (7/10): The company carries no debt, and its Altman-Z score of 8.23 signals virtually no bankruptcy risk. Liquidity is strong, with a quick ratio of 2.85. The only minor concerns are a slight increase in shares outstanding over time.
-
Valuation (8/10): The stock is attractively priced relative to its industry on P/E, forward P/E, and enterprise value to EBITDA. The PEG ratio confirms its value once growth is factored in.
-
Growth (9/10): Past EPS and revenue growth are both strong, and forward estimates call for 34.65% annual EPS growth and 14.75% revenue growth over the next several years.
Where to Find More Opportunities
The Peter Lynch screen isn’t limited to just one stock—it’s a framework that can uncover a range of GARP candidates across different sectors. If you’re interested in exploring additional companies that meet these same criteria—sustainable growth, reasonable valuation, and strong fundamentals—you can run this screen yourself and see the full list. Click here to access the Peter Lynch stock screener and start your own analysis.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Always conduct your own research and consult with a qualified financial professional before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Neurocrine Biosciences (NASDAQ:NBIX) Fits the Profile of a Classic GARP Stock Under the Peter Lynch Framework
Neurocrine Biosciences (NBIX) fits the profile of a company that could appeal to investors seeking a blend of growth and value—often referred to as GARP (Growth at a Reasonable Price). This strategy, famously championed by legendary fund manager Peter Lynch, focuses on identifying companies that are expanding their earnings at a sustainable pace while trading at valuations that don’t fully reflect that potential. Lynch’s approach, detailed in his book One Up on Wall Street, emphasizes buying growing businesses with solid fundamentals and reasonable price tags, steering clear of overhyped stocks. He also advocates for patience and long-term holding, letting compounding work its magic over years rather than months.
Neurocrine Biosciences (NASDAQ:NBIX) is a neuroscience-focused biopharmaceutical company with approved treatments for conditions like tardive dyskinesia and Huntington’s disease-related chorea, as well as a pipeline targeting neurological, neuroendocrine, and neuropsychiatric disorders. Below, we break down why NBIX earns strong marks under the Peter Lynch framework and what this means for GARP-oriented investors.
Why Neurocrine Biosciences Fits the Peter Lynch Screen
The Peter Lynch screen is built around a core set of criteria designed to weed out both stagnant and dangerously fast-growing companies while highlighting those with healthy financials and attractive valuations. NBIX passes every major test, often by a wide margin.
Sustainable Earnings Growth Lynch insisted that earnings per share (EPS) grow between 15% and 30% annually over five years—fast enough to drive returns but not so fast that growth becomes unsustainable. NBIX delivers a 5-year EPS growth rate of 29.09%, right at the upper end of his ideal range. This growth is backed by a strong revenue trajectory of 22.29% annually over the same period, and recent revenue growth accelerated to 28.59% in the past year. The company’s expansion is grounded in real commercial success, particularly with its lead drug INGREZZA.
Valuation That Compensates for Growth The PEG ratio (price/earnings divided by earnings growth) is a cornerstone of Lynch’s method. He looked for a PEG below 1.0, signaling that the stock isn’t overpriced relative to its growth rate. NBIX’s PEG (based on past 5-year growth) stands at 0.86, well within that threshold. Its trailing P/E of 24.88 is actually cheaper than 93.57% of peers in the biotechnology industry, while its forward P/E of 16.74 undercuts the S&P 500’s forward multiple of 21.01. In short, you’re paying a reasonable price for above-average growth.
Financial Health and Profitability Lynch favored companies with strong balance sheets and high returns on equity, viewing them as safer long-term bets. NBIX has zero debt—its Debt/Equity ratio is exactly 0.0—and a current ratio of 2.93, meaning it has nearly three times the current assets needed to cover short-term liabilities. Return on Equity (ROE) is 19.62%, comfortably above the 15% minimum in the screen. These metrics confirm a business that is profitable, well-capitalized, and not reliant on borrowing to fund growth.
Additional Lynch-Friendly Traits Beyond the headline filters, Lynch liked companies that buy back shares, have manageable institutional ownership, and generate ample cash. NBIX’s return on invested capital (ROIC) of 13.53% outperforms 95% of its industry peers, and its free cash flow is strong. While the company does not pay dividends (common for growth-stage biotechs), its capital allocation focuses on reinvesting in its pipeline, which aligns with long-term value creation.
High-Level Fundamental Report Summary
Our fundamental analysis of NBIX awards it a strong overall rating of 7 out of 10, which reflects a company with solid profitability, excellent health, and attractive growth at a fair valuation.
Profitability (8/10): NBIX’s profit margin of 21.55% and operating margin of 25.75% are among the best in the biotechnology industry. Return on assets and return on invested capital both rank in the top 5% of peers.
Health (7/10): The company carries no debt, and its Altman-Z score of 8.23 signals virtually no bankruptcy risk. Liquidity is strong, with a quick ratio of 2.85. The only minor concerns are a slight increase in shares outstanding over time.
Valuation (8/10): The stock is attractively priced relative to its industry on P/E, forward P/E, and enterprise value to EBITDA. The PEG ratio confirms its value once growth is factored in.
Growth (9/10): Past EPS and revenue growth are both strong, and forward estimates call for 34.65% annual EPS growth and 14.75% revenue growth over the next several years.
Where to Find More Opportunities
The Peter Lynch screen isn’t limited to just one stock—it’s a framework that can uncover a range of GARP candidates across different sectors. If you’re interested in exploring additional companies that meet these same criteria—sustainable growth, reasonable valuation, and strong fundamentals—you can run this screen yourself and see the full list. Click here to access the Peter Lynch stock screener and start your own analysis.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Always conduct your own research and consult with a qualified financial professional before making investment decisions.
Read full article here »